secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2023-08-22T23:59:59+00:00
Accession:  0001437749-23-024370
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen appoints Cindy Anderson as CFO; Jerrold Dotson retires after decade-long tenure
--------------------------------------------------------------------------------

- Cindy Anderson appointed CFO effective August 21, 2023, succeeding Jerrold Dotson upon his planned retirement.
- Anderson brings 15+ years biopharma experience, most recently Chief Accounting Officer at Alnylam Pharmaceuticals (ALNY).
- She previously held senior finance roles at Alexion Pharmaceuticals and began her career at PwC and EY.
- No arrangements or related-party transactions exist in connection with Anderson's appointment.
- CEO Shawn Singh expressed gratitude for Dotson's decade of service and welcomed Anderson's financial expertise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000143774923024370/0001437749-23-024370-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000143774923024370/vtgn20230821_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-024370

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer